Compare Amphastar Pharmaceuticals Inc (AMPH) vs Byrna Technologies Inc (BYRN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BYRN trades at $3.865, down 1.9% today, with a bearish technical signal from moving averages and oscillators. Recent Q2 2026 results showed a significant revenue decline of 42.5% year-over-year and a net loss of $0.44 per share, missing estimates. The company faces challenges in sales and marketing effectiveness but is undertaking strategic initiatives including a recent acquisition and marketing overhaul to revive growth.

The outlook remains cautious due to persistent profitability issues and negative cash flow trends. While analyst consensus is predominantly Buy (71%), reflecting long-term potential in the less-lethal defense market, near-term risks from execution missteps and competitive pressures warrant careful monitoring. Investor sentiment is mixed amid ongoing operational reset efforts.